Early diagnosis and treatment of PAH improve survival

Robyn Kalda
Jan 19
1 min read

This study examined the causes of delayed diagnosis (diagnosis after approximately 22 months) of pulmonary arterial hypertension (PAH) and whether an earlier diagnosis (within six months) leads to better outcomes. They identified several factors associated with delayed diagnosis and found that earlier diagnosis and treatment were associated with better survival.

Read the Pulmonary Circulation article

Recent Posts

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Sotatercept lowers blood volume but increases exercise ability

In a study of a relatively low-risk population of pulmonary hypertension patients, researchers began to untangle sotatercept's complex effects on exercise. Sotatercept lowered blood volume to normal l

Comments